Eden Research Share Price (EDEN)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.85 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
3.70 4.00 3.85 3.85 3.85
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.23 -3.40 -0.73 15
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 3.85 GBX
Related Shares
Astrazeneca (AZN), Gsk (GSK), Motif Bio (MTFB), Bermele (BERM)

Eden Research (EDEN) Latest News

Eden Research News

Date Time Source Headline
29/6/202221:29ALNCTRADING UPDATES: Aquila closes acquisition; Mila's "impressive" assays
29/6/202212:18UKREGEden Research plc Result of AGM
29/6/202207:00UKREGEden Research plc AGM Statement
08/6/202207:12UKREGEden Research plc Notice of AGM & Publication of Annual Report
07/6/202207:00UKREGEden Research plc Investor Meet Company: 2021 Results Presentation
31/5/202212:00ALNCIN BRIEF: Eden Research widens annual loss as costs up, Covid impacts
31/5/202210:29UKREGEden Research plc Director/PDMR Shareholding
31/5/202207:01UKREGEden Research plc Preliminary results
16/5/202217:05UKREGEden Research plc Holding(s) in Company
13/5/202208:45ALNCCORRECT: Eden Research passes milestone for US okay of crop protection
More Eden Research News
Eden Research Investors    Eden Research Takeover Rumours

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
06/7/202210:43Eden Research12,549
31/3/202214:47Eden....Onward and Upwards!50
29/3/202216:04Eden Research14
29/3/202214:36Eden Research - Who Is Behind Thallo Eco Products Corp?27
29/3/202214:35Plus Market3

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-07-05 14:34:453.9310,006393.64O
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

DateSubject
06/7/2022
09:20		Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 3.85p.
Eden Research Plc has a 4 week average price of 3.75p and a 12 week average price of 3.75p.
The 1 year high share price is 11.30p while the 1 year low share price is currently 3.75p.
There are currently 380,340,229 shares in issue and the average daily traded volume is 282,386 shares. The market capitalisation of Eden Research Plc is £14,643,098.82.
Read Full Thread
Reply
01/7/2022
11:29		neutralpov: lol, the lying rampers even boast about their multi-avatars they use to manipulate the ticks - as if the ticks matter to anyone!! ;D THE ONLY TICKS THAT MATTER are the downticks in the EDEN share price! Yes... ALL YOU NEED TO KNOW IS ALREADY HERE (see below): EDEN BOILER ROOM SC*M Ignore the pimping by the paid rampers (investingisatrickygame, barrelboy + socks), morons (supersonico, Timbo_Slice aka forger NEUTRAiPOV) and trolls. The chart says it all.
Read Full Thread
Follow
Reply
01/7/2022
11:19		neutralpov: All these fantasies as above are already FULLY BUILT-IN TO THE SHARE PRICE. Which share price sez EDEN is sheeeeeeeeeeeeeeeyit. :p
Read Full Thread
Follow
Reply
01/7/2022
11:01		investingisatrickygame: Super IMO, Eden has laid down an excellent platform to catapult their business and of course, in a regulatory, lab and field testing environment, this takes time to materialise commercially. I'm sure all those invested in Eden have learnt along the way. They are protected with their IP and Patents, lifespan extended in the EU They are beginning to have reach and will have a lot more in less than a year. some sooner They will shortly be a multi-product commercialised business, not simply dependent on one product and one region The new product markets are getting bigger (seeds and insecticides) And they have still yet, to independently commercialise Sustaine although this is being trialled as previously RNS'd They are aligned with global industry parties who are successful in their own right and who will undoubtedly help make Eden successful through product sales It is clear sales are low, but we have been through an unprecedented time this last two years, combined with Eden seeking more regulatory approvals. So, if an investor is looking at current sales and the share price, they will be unimpressed However, if investors look at achievements during the same period which will now deliver sales, they will better understand Eden and realise how much has been achieved and what the inherent value is in Eden today
Read Full Thread
Follow
Reply
24/6/2022
20:50		neutralpov: NeutraIPOV 24 Jun '22 - 16:27 - 12384 > The usual EDEN is doomed posts from the same usual nut jobs and non holders… erinvale1 24 Jun '22 - 16:31 - 12385 > I recall you repeating that Eden is headed to zero pence. You are uttering the usual unhelpful and uninformative nonsense. @ erinvale1 You have been hoodwinked by one of the bushed/hawthorny ramping team, who forges my username. My username has a lower-case "L" as its 7th character. The forger's one has an upper-case "i" there instead. Spotted it? That's how low these crooks play ... a counterfeiter and fake. RENEWED TARGET share price FOR EDEN.L ZERO PENCE (0.0000 p)
Read Full Thread
Follow
Reply
17/6/2022
15:40		investingisatrickygame: Cenkos Report 2022 Page 6, available for anyone to read. Link on Eden's website. A £197 million per annum future opportunity based on proven and developed/developing products. Eden Research market opportunities We analyse the potential for Eden Research’s currently marketed and pipeline opportunities in more detail in this report, providing an overview of the market potential below. In aggregate, we believe Eden Research is targeting significant market opportunities, which could transform the company in the near- to mid-term.  Mevalone – Grapes in the Southern EU zone. Assuming a market share of 10%, we estimate this opportunity could be worth c£10m to Eden Research.  Mevalone – Apples/grapes in the Central EU zone. Assuming a market share of 10%, we estimate this opportunity could also be worth c£10m to Eden Research.  Cedroz – We estimate the potential revenues for Cedroz to treat nematodes in the markets covered by the Eastman Chemicals could be c£24m assuming a 10% market share.  Insecticide – Combining the US and European markets, we estimate the insecticide opportunity could be worth c£58m assuming a 10% market share.  Seed treatment – Eden Research’s seed treatment development with Corteva has the potential to generate c€40m of sales to the company per year.  Sustaine opportunities – Eden Research estimate that the two lead development projects for Sustaine could generate a combined c£60m per year revenue opportunity.
Read Full Thread
Follow
Reply
16/6/2022
23:06		neutralpov: ravenna23 16 Jun '22 - 13:24 - 12255 wrote to the Troll: You don’t hold You work for a boiler room or Hawthorn PR The Eden price has fallen 80% in the past year Where am I wrong? I am warning the public off this share Why are you here as a pale imitation of another? BIG FRAUD ========= You asked "Where am I wrong?" It actually fell 81-82% since last February. Not 80% in the last 12 months. And the forger and Identity Thief is merely a troll, not a paid ramper. Otherwise, correct.
Read Full Thread
Follow
Reply
02/6/2022
16:11		neutralpov: Good grief, you are crazy. These have no possible bearing on EDEN share price and prospects. Suggest you go back to Melinda Gates's cycle - that has more relevance. :D
Read Full Thread
Follow
Reply
27/5/2022
13:52		neutralpov: Ignore the sadistic troll (and forger and crook) above. He has no skin in this game. --- Look at the spectacle of the share price chart. Another few ticks downwards as the shares dumped by Amati are starting to worry the middlemen... today's transactions indicate that one can BUY almost any number at 4.69 pence... yes, BUY. So how the midmarket share price shown here can be 4.75p is a little mystery. And try to sell anything more than a few thousand... hahahaha.... 4p. And a significant number, who knows. 2p? 1p? 0.1p? RESTATED TARGET share price ..... ZERO PENCE (0.000 pence) Ignore the sadistic troll, the madwoman, the paid ramper. Their opinions do not count. Face reality before it smacks you in the face less than five weeks from today. On 9 June, IIRC, we are due another list of significant shareholdings. :) That should provide a lot of entertainment, specially re the ijjit PI.
Read Full Thread
Follow
Reply
20/5/2022
12:48		supersonico: 2017 was the time line prediction that JakNife (aka the guy who could not say Cedroz) prematurely made on EDEN's demise. I would happily show you his post but he went all sheepish on Eden and deleted all his posts which is odd for a person with such conviction. You suggest 'Next couple of years' Next couple of years ? and not soon after accounts get published after the FRC intervene and investors including II's who have already witnessed FRC commentary get wind of something more concerning than already has been disclosed by the company that you keep alluding to? 'Next couple of years' bring us to 2024. 2024 is when the Corteva deal is planned to kick off so even a further fund raise and dilution may well be countered and the share price supported by the run up to or the roll out of the biggest deal Eden has announced to date.. and what they have stated so far only includes Europe so we still await a rest of the world / regional announcements which I assume Corteva will be keen to pursue once this first round of the process is concluded. Also don't forget the US Cedroz approvals of Mev and Ced which will have a positive impact on the share price in between times I imagine. While I appreciate your reply the picture you imagine Sounds like an unlikely scenario to me.
Read Full Thread
Follow
Reply
18/5/2022
14:45		supersonico: NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ..................................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% hTTps://www.edenresearch.com/investors/securities_information.aspx
Read Full Thread
Follow
Reply
Eden Research share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220706 10:21:55